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Elevation of CSF N-acetylaspartylglutamate (NAAG) in some
leukodystrophies has been previously described but its relationship
to disease is poorly understood, with the exception of Canavan disease
where the elevation of N-acetylaspartate (NAA) may be directly
implicated [1].
Using two capillary electrophoresis systems, NAAGhas been shown
to be elevated in the CSF of 29 out of 32 patients with a clinical
presentation of Pelizaeus–Merzbacher disease (PMD) [2]. This includ-
ed 22 patients with PLP1 mutations and 7 patients with Pelizaeus–
Merzbacher-like disease (PMLD). However, the nature of the muta-
tions was not reported either in the PMD or the PMLD groups. An
increase of NAAG was also observed in the CSF of one patient with
Canavan disease [3], one PMLD patient harboring a homozygous
deletion in the GJC2 gene [4] and two patients with a severe
hypomyelination pattern of unknown cause [5]. In addition, werecently reported that CSFNAAGwas increased in 6 patientswith sialic
acid storage disease (SASD) associated with SLC17A5mutations [6].
Therefore, we decided to use proton NMR spectroscopy (1H-NMRS)
to determinewhether the levels of CSFNAAGcan facilitate themolecular
diagnosis of patientswith leukodystrophieswith a hypomyelinating or a
non-hypomyelinating pattern on brain MRI [7].
2. Material and methods
2.1. Patients
Seventy-four children and adults from two referral centers for
neurogenetics and neurometabolismwere enrolled in clinical protocols
approved by the ethics committees of the Hôpital de Clermont-Ferrand,
France, and theNational Institutes of Neurological Disorders and Stroke,
Bethesda, MD, USA. Written informed consent was obtained from all
patients or their legal guardians.
The cohort of patientswith leukodystrophieswith a hypomyelinating
pattern consisted of (i) 26male patients with PLP1mutations presenting
as PMD or X-linked spastic paraplegia type 2 [8]–PMD/SPG2 patients–
including 19 patients with PLP1 duplication and 7 patients with PLP1
missense or splice mutations (Table 1); (ii) 9 patients with PMLD
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leukodystrophy of unknown etiology despite extensive metabolic and
genetic testing. The rest of the cohort consisted of 14 patients with
leukodystrophies with a non-hypomyelinating pattern–including
patients with Canavan disease, merosin deﬁciency, MLC1 mutation and
complex I deﬁciency–and 15 diseased controls with complex neurolog-
ical diseases but normal brain MRI.
2.2. Methods
In order to assess clinical severity, we used a score previously
validated in patients with PLP1mutations [9]. Brieﬂy, form 0 referred
to absence ofmotor achievement; form 1–head control between 2 and
4 years; form 2–sitting position between 2 and 5 years; form 3–sitting
position between 1 and 2 years, walk with support at a mean age of
3.5±1.5 years (range 2–6); form 4–autonomous walking.
Frozen CSF–stored at −80 °C–were prepared for 1H-NMRS with
minimal handling [5,10]. First, CSF samples were deproteinized using a
10 kDa ﬁlter (Nanosep, Omega) to avoid interference from high
molecular weight species such as lipoproteins. Before use, the ﬁlter
was washed twice with water by centrifugation to remove glycerol. A
100 μl aliquot of 3.89 mM[trimethylsilyl]-2,2,3,3-tetradeuteropropionic
acid in 2H2O (TSP-2H2O, Aldrich) was then added to 500 μl of the
ultraﬁltrate, providing a chemical shift reference (δ=0.00 ppm), a
concentration reference and a deuterium lock signal. The pH of the
ultraﬁltrate was adjusted to 2.50±0.05 with concentrated HCl. Finally,
500 μl of the sample was placed in a 5 mm NMR tube (Wilmad Royal
Imperial). The proton NMR spectra were determined on an Avance-500
SB spectrometer (Bruker, France) equipped with a 5 mm BBI (broad-
band inverse) probe; samples were not spun. Spectra were collected at
25 °C and consisted in 32 K data points with a spectral width of 6000 Hz
and a total acquisition times of 27 min. A 90° radiofrequency pulse,
following a water signal presaturation of 10 s, was used for each 128
scans. Shimming of the sample was performed on the deuterium signal
until the resonance line width for TSP was b1 Hz. Before a Fourier
transformation into 64 Kdata points, a sinewindowmultiplication (sine
bell shift of 90°) was used to reduce noise. The phase and the baselineTable 1
Genetic, biochemical and clinical characteristics of PMD/SPG2 patients.
PLP1 mutation NAAG (μmol/L)a Age Clinical score
p.Cys109TrpfsX11 ND 3 3
p.Asp103ThrfsX12 ND 17 3
p.Val219Phe ND 38 3
c.IVS4+1GNA / p.Val209GlufsX27 ND 9 3
p.Leu223Phe 38 10 0
p.Cys220Tyr ND 10 3
p.Asp103ThrfsX12 ND 18 4
Duplication 30 2 1
Duplication 36 6 3
Duplication 40 2 2
Duplication 65 6 3
Duplication 89 5 3
Duplication 32 17 2
Duplication 84 8 2
Duplication 60 11 3
Duplication 47 4 3
Duplication 106 13 2
Duplication 36 8 3
Duplication 56 5 2
Duplication 205 8 1
Duplication 88 9 1
Duplication 55 3 1
Duplication 32 5 2
Duplication 23 3 1
Duplication 53 5 3
Duplication 52 7 2
a Diseased controls, mean=5±1 μmol/L (n=15). ND: below detection limit
(b3 μmol/L).were correctedmanually using the spectrometer software (X-WinNMR
3.5, Bruker, France). Two-dimensional proton NMRS, 1H–1H correlation
spectroscopy (COSY), was performed to conﬁrm the identiﬁcation of
metabolites of interest in patients' body ﬂuids. The spectra were
recorded at 500 MHz using 4 k datapoints in F2 and a spectral width of
6002 Hz. 256 Increments and 16 scans per incrementwere used. The TR
was 1.5 s, during which the water resonance was presaturated. Prior to
Fourier transformation, a sine window multiplication was applied in
both time domains. The values of NAAGwere calculated by comparison
with the known concentration of the internal standard (TSP).
A one-way between groups analysis of covariancewas conducted to
compare the levels of CSF NAAGbetween PMD/SPG2 patientswith PLP1
duplication and PLP1 point mutations using age and clinical score as
covariates. Preliminary checkswere conducted to ensure that therewas
no violation of the assumptions of normality, linearity, homogeneity of
variances and homogeneity of regression slopes.
3. Results
3.1. Elevated CSF NAAG in patients with PLP1, GJC2 and ASPA mutations
In a 1-dimensional 1H-NMR spectrum (pH=2.5), NAAG presents
as a prominent singlet resonance at 2.04 ppm and smaller resonances
at 2.01 and 2.23 (multiplets), 2.47 (triplet), 2.81 and 2.91 (doublet of
doublets), 4.32 (doublet of doublets), and 4.72 ppm (doublet of
doublets) [11]. Characteristic cross peaks in 2-dimensional COSY 1H-
NMRS are shown in Fig. 1.
Compared to our group of disease controls, in vitro 1H-NMRS of CSF
showed a signiﬁcant elevation of NAAG in the CSF of PMD/SPG2 patients
compared to controls (47±44 μmol/L vs. 5±1 μmol/L, pb0.001). The
meanvaluesofNAAGwerenormal in (i) patientswithPMLD, (ii) patients
with other leukodystrophies with a hypomyelinating MRI pattern, and
(iii) patientswith leukodystrophieswith a non-hypomyelinating pattern
(Fig. 2). However, 1H-NMRS revealed amild tomoderate elevation in the
CSF of one PMLD patient associated with GJC2 compound heterozygous
mutations (14 μmol/L), one patient with Canavan disease associated
with ASPA mutations (17 μmol/L), and two patients presenting with a
hypomyelinating leukodystrophyof unknownetiology (33 and60 μmol/
L respectively) (Fig. 2). Of note, we did not observe any CSF elevation of
NAA except in the CSF of the patient with Canavan disease (98 μmol/L,
Fig. 3).
3.2. Association of elevated CSF NAAG with the nature of the PLP1
mutation rather than clinical severity
1H-NMRS revealed an elevation of NAAG in the CSF of all 19
patients with PLP1 duplication (Table 1 and Fig. 2). Conversely, CSF
NAAG was strictly normal in 6 out of 7 patients with PLP1 missense,
nonsense or splice mutations (Table 1 and Fig. 2). The only patient
with PLP1 mutations who displayed a signiﬁcant elevation of CSF
NAAG presented with the most severe clinical presentation—clinical
score of 0 (Table 1). However, there was no correlation between the
levels of CSF NAAG and clinical severity among the cohort of PMD/
SPG2 patients, or among patients with PLP1 duplication only. There
was no correlation either between CSF NAAG and age. Moreover,
when adjusting for both age and clinical severity, we found a
signiﬁcant elevation of NAAG in patients with PLP1 duplication versus
PLP1 point mutations (p=0.012, partial eta squared=0.265).
Therefore, the elevation of NAAG in the CSF of PMD/SPG2 patients
strongly suggests the nature of the mutation–i.e. duplication in the
PLP1 gene–rather than clinical severity.
4. Discussion
In this study, using in vitro 1H-NMRSweshowed thatNAAG is always
elevated in the CSF of patientswith PLP1duplication.We also conﬁrmed
Fig. 1. One-dimensional and 2-dimensional (COSY) 1H-NMR spectra of NAAG in CSF. The upper part shows the methyl signal (CH3 of NAAG) in the 1D spectrum (2.04 ppm). The
lower part shows the correlations between the two diastereotopic protons of CH2 (H17)–2 doublets of doublets at 2.91 and 2.85 ppm–and the correlations between the two
diastereotopic protons of CH2 (H8)–multiplets at 1.99 and 2.23 ppm–and the two protons of CH2 (H9)–triplet at 2.43 ppm–in the 2D spectrum. The signals of protons of CH2 (H8)
and CH2 (H9) are not visible on the 1D spectrum because of their small intensities and overlap with glutamate and methyl signals.
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Fig. 2. Valuesof CSFNAAG in the cohortof 74patients. Thedotted line represents theupper
limit of normal values of CSF NAAG (12 μmol/L [5]). DUP: duplication; MUT: point
mutation; PMLD: Pelizaeus–Merzbacher-like disease; UL: unknown leukodystrophy.
Circles and stars denote outliers that are farther than 1.5 and 3 interquartile ranges
respectively from the nearer edge of the box.
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disease [2,3]. Despite the elevation of CSF NAAG in one patient with a
PLP1pointmutation displaying a very severe form of the disease,we did
not ﬁnd any correlation between the levels of CSF NAAG and clinical
severity in PMD/SPG2 patients, which is consistent with our recent
ﬁndings in SASD patients [6]. Since we had relatively few patients with
mutated PLP1 and severe clinical score (0–1), we cannot completely
exclude that some patients with severe missense mutation also have
elevated CSF NAAG. Nevertheless, there was a marked difference in the
levels of CSF NAAG between the patients with PLP1 duplication and
those with PLP1 point mutations, even when adjusting for clinical
severity. Therefore, we suggest that quantifying NAAG levels in CSF of
patients with white matter diseases can be a useful and simple tool to
orient molecular diagnostic testing, especially in hypomyelinating
leukodystrophies. Of note, in vivo 1H-MRI spectroscopy is unable to
provide similar information since the technique cannot discriminate
between the NAA and NAAG peaks unlike in vitro 1H-NMRS (Fig. 3).
Consequently, the relatively high NAA concentrations in brain tissues
prevent the measurement of NAAG in vivo. The detection limit of 1H-
NMRS for CSF NAAG is higher than of techniques such as two capillary
electrophoresis [2] or mass spectrometry (personal observation).
However, contrary to these techniques, 1H-NMRS requires no deriva-
tizationor extraction. It can therefore simultaneouslydetect compounds
of different nature which allows the non-a priori identiﬁcation of new
metabolic abnormalities in patients with uncharacterized or known
genetic diseases [6,12].
The absence of correlation between CSF NAAG and clinical severity in
PMD/SPG2 and SASD patients, as well as the observed neuroprotective
effect of increased extracellular NAAG during GCPII inhibition [13],
suggest that NAAG is an unlikely contributor to the hypomyelination
phenotype observed in these patients. NAAG undergoes a tricellular
metabolic sequence wherein it is synthesized in neurons from N-
acetylaspartate (NAA) and L-glutamate, hydrolyzed to NAA and
glutamate by astrocytes and further hydrolyzed to L-aspartate and
acetate by oligodendrocytes [14]. NAA was also shown to provide acetyl
groups formyelin synthesis [15]. It is therefore possible that the elevation
of CSFNAAG in somehypomyelinating disorders reﬂects a compensatory
mechanism for the alteredmaturation of oligodendrocytes in an effort to
enhance myelin synthesis.
The elevation of CSF NAAG in patients with PLP1 duplication, but
usually not in patientswithpointmutations, favors a speciﬁc effect of the
over-expressed wild-type PLP1 gene as supported by in vitro and
preclinical in vivo studies [16,17]. Overexpression ofwild-type PLP in theCNS may affect the integrity of neurons as suggested by the increased
mortality of neurons when cultured in the presence of conditioned
media fromPLP overexpressing cells but not fromDM20–a splice variant
of PLP–overexpressing cells. This effect of conditioned media may be
mediated by a negative pH shift elicited by PLP [18] and could be related
to thesimilarity of PLPand its fourhydrophobic domainmotif to proteins
that are known to function as pores or channels [19]. Interestingly,
abnormal connexin 47 associated with GJC2 gene mutations was
reported to alter the function of intercellular channels [20]. The sialin
transporter, which was recently found to also function as an aspartate
transporter [21], may have a role in neuronal secretory processes due to
its additional non-lysosomal localization [22]. Therefore, the implication
of PLP1, connexin 47 and sialin in the formation of ion channels/
transporters in membranes suggests increased excretion of NAAG into
the extracellular compartment. The lack of concurrent elevation of NAA
further supports the hypothesis that NAAG elevation in CSF of patients
with PLP1 duplication results from excessive neuronal release of NAAG
rather than from its over-production.We found two patients presenting
with hypomyelination on brain MRI and increased CSF NAAG but
without mutations of PLP1, GJC2 or SLC17A5. A similar entity has been
previously reported [5]. In these cases, a candidate genes approach
should focus on genes encoding for proteins related to the structure and
function of ion channels or transporters.
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